VISION 2013.

Methods	No participant received lipid‐altering agents; no wash‐out period was required 12‐Week randomised trial
Participants	42 men and women with hyperlipidaemia aged 45 to 75 years 21 participants received pitavastatin; 21 received atorvastatin Exclusion criteria: age < 20 years, premenopausal females, diabetes, CVD, liver and renal dysfunction, endocrine disease, administration of agents that could affect lipid metabolism and oxidation Atorvastatin baseline TC: 6.96 mmol/L (269 mg/dL) Atorvastatin baseline LDL‐C: 4.73 mmol/L (183 mg/dL) Atorvastatin baseline HDL‐C: 1.42 mmol/L (55 mg/dL) Atorvastatin baseline TG: 1.49 mmol/L (132 mg/dL)
Interventions	Pitavastatin 2 mg/d Atorvastatin 10 mg/d
Outcomes	Per cent change from baseline at 12 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	Pitavastatin group was not included in the efficacy analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	All lipid parameters were included in the efficacy analysis
Other bias	Low risk	Industry did not fund the trial